Anti-Human TIM-3 (HAVCR2) (Clone CPTC-HAVCR2-1) – Purified No Carrier Protein

Human HAVCR2 synthetic peptide sequence GACPVFECGNVVLR

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Liquid

Purified antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

FSAI172-2E12 activity is directed against human HAVCR2 peptide sequence GACPVFECGNVVLR.

CPTC-HAVCR2-1

HAVCR2 (also known as TIM-3) is a member of the T cell immunoglobulin mucin gene family and encodes a type I membrane protein consisting of an immunoglobulin variable-region-like domain, a mucin-like domain, and a tyrosine phosphorylation motif¹. HAVCR2 functions as an important immune checkpoint receptor that helps regulate dendritic cell function², T helper type I expansion, and induction of peripheral tolerance³. HAVCR2 interacts with GAL-9, PtdSer, HMGB1 and CEACAM1 to activate biochemical pathways such as immune tolerance, T cell depletion, NF-κB signaling, and IL-2 secretion⁴. Additionally, HAVCR2 expression correlates with terminal differentiation and exhaustion in tumors as well as chronic infection³. Due to its dysregulation in different types of cancer, HAVCR2 blockade is being investigated as an anti- tumor immunotherapy^2,4. HAVCR2 also has potential as a prognostic marker in solid tumors⁴.

FSAI172-2E12 was generated in mouse for use in immuno-MRM assays using a synthetic peptide derived from residues 56-69 of human HAVCR2 that is carbamidomethylated at the cysteine residues, GAC[cam]PVFEC[cam]GNVVLR⁵. FSAI172-2E12 does not detect HAVCR2 by reverse phase protein array or as recombinant protein by Western blotting⁶. FSAI172-2E12 may detect HAVCR2 in cell lysates of A549 and MCF7. The observed band ran higher than expected, but this may be due to glycosylation.

HAVCR2 is expressed on T cells, including regulatory T cells and Th1 cells, dendritic cells, and natural killer cells. HAVCR2 is also expressed on CD8⁺T cells in the tumor microenvironment as well as intratumoral macrophages and monocytes. HAVCR2 is expressed by Th1 cells after several rounds of polarization in vitro. HAVCR2 is not expressed by naïve T cells.

Galectin-9

1 Monney L, Sabatos CA, Gaglia JL, et al. Nature. 415(6871):536-541. 2002.
2 Dixon KO, Tabaka M, Schramm MA, et al. Nature. 595(7865):101-106. 2021.
3 Sabatos CA, Chakravarti S, Cha E, et al. Nat Immunol. 4(11):1102-1110. 2003.
4 Sauer N, Janicka N, Szlasa W, et al. Cancer Immunol Immunother. 72(11):3405-3425. 2023.
5 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
6 https://antibodies.cancer.gov/detail/CPTC-HAVCR2-2